Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.61 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14568338 | 0.93 | HSP90AA1 (0.54) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL3895758 | 0.89 | HSP90AA1 (0.78) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL10236785 | 0.86 | HSP90AA1 (0.57) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL311457 | 0.85 | HSP90AA1 (0.61) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312686 | 0.81 | HSP90AA1 (0.80) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312558 | 0.80 | HSP90AA1 (0.72) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312321 | 0.79 | HSP90AA1 (0.77) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312322 | 0.79 | HSP90AA1 (0.77) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312592 | 0.78 | HSP90AA1 (0.75) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312593 | 0.78 | HSP90AA1 (0.75) | HSP90AA1TRAP1HSP90B1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885TRAP1 8/4885HSP90B1 4/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885TRAP1 9/4885HSP90B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.